Aktis Oncology Inc
Research Aktis Oncology Inc (AKTS) on Bullrun: market cap USD 1.00B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAKTS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.00B
- Financial periodQ2 2026
- RevenueUSD 3.38M
- Net income-USD 24.14M
- Free cash flow-USD 21.85M
Valuation Snapshot
latest market cap is USD 1.00B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.50M | -USD 63.73M | -USD 73.71M | n/a | -1.21 | USD 37.78M | USD 11.55M | -USD 146.15M |
| FY2024 | USD 27.38M | -USD 167.95M | -USD 46.34M | -2.5% | -1.89 | USD 24.45M | USD 52.86M | -USD 57.09M |
| FY2023 | USD 27.12M | -USD 63.56M | -USD 56.21M | -11.5% | -1 | USD 43.10M | USD 45.43M | USD 86.24M |
| FY2022 | USD 15.35M | -USD 59.03M | -USD 72.92M | -27.0% | -1.09 | USD 80.49M | USD 44.86M | USD 103.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.00B | n/a | n/a | n/a |
About Aktis Oncology Inc
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aktis Oncology Inc's market cap?
Aktis Oncology Inc's market capitalization is USD 1.00B.
What does Aktis Oncology Inc do?
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.